South Africa's Aspen in $1 billion deal with Merck
JOHANNESBURG (Reuters) - Aspen Pharmacare said on Thursday that it would acquire drugs and a plant from U.S. firm Merck in a $1 billion deal that bolsters its presence in Europe, Latin America and Asia.
Africa's biggest maker of generic drugs said it would buy an active pharmaceutical ingredient (API) business located in the Netherlands and a portfolio of 11 drug brands from Merck.
Aspen said the deal was subject to the approval of various competition authorities and the South African Reserve Bank.
Last week, Aspen said it would acquire the Arixtra and Fraxiparine/Fraxodi brands of thrombosis drugs from GlaxoSMithKline, except in China, Pakistan and India, a deal that could also be worth $1 billion.
Shares in Aspen, rose more than 1 percent on the news, outperforming a 0.7 percent decline in Johannesburg's benchmark Top-40 index.
(Reporting by Tosin Sulaiman and Tiisetso Motsoeneng; editing by David Dolan)
LONDON - European shares inched up on Friday with riskier assets still in demand following a broadly neutral shift in U.S. monetary policy, and the euro dipped after a credit agency cut its rating on the European Union.
WASHINGTON - Start-up companies will be able to raise much more capital through certain public stock deals without facing costly regulatory burdens under a proposal announced by U.S. securities regulators on Wednesday.
BEIJING/HONG KONG - China reiterated its opposition on Thursday to a European Union plan to limit airline carbon dioxide emissions and called for talks to resolve the issue a day after its major airlines refused to pay any carbon costs under the new law.